The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
31
No.
34
September 23, 2005
- NCI, NHGRI plan $100-million, three-year feasibility test for cancer genome project. NCI to establish biospecimen office.
- Matrisian, Nelson, to lead review of NCI translational research programs.
- House panel examines use of grant funds.
- No difference between digital or film mammograms, study finds.
- Gritz is president-elect of Society for Research on Nicotine and Tobacco.
- NCI, NSF fund awards in nanotech training.
TCL
Vol.
31
No.
35
September 30, 2005
- White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.
- Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”
- Members of Congress say that won’t work.
- Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.
- After a “humble” start at NCI, von Eschenbach set unachievable goal.
CCL
Vol.
28
No.
9
September 30, 2005
- ASCO Backs Sentinel Node Biopsy In Some Early Stage Breast Cancer
- Breast Cancers Detected By Mammograms Have Better Prognosis, Trials Analysis Finds
- Herceptin Reduces Recurrence In Early HER2+ Breast Cancer
- Frozen Section Analysis Helps Avoid Second Surgery
- Breast Cancer Family History Doesn’t Increase Risk Of Ovarian Cancer, Study Says
- Arimidex Gets Full Approval For HR+ Early Breast Cancer
- Mozobil Plus G-CSF Increases Rate Of Cell Mobilization
- Endoscopic Surgery Provides Equal Or Better Results
- Aranesp Improved Anemia In MDS In Phase II Trial
- NCI Cooperative Group, Cancer Center Trials Listed
TCL
Vol.
31
No.
36
October 07, 2005
- Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge?
- John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions.
- Cancer death rate dropping 1.1 percent a year, annual report finds.
TCL
Vol.
31
No.
37
October 14, 2005
- Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.
- Capitol Hill: With money tight, support for 2015 goal is symbolic.
- Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.
- NCI selects nanotech centers for funding.
TCL
Vol.
31
No.
38
October 21, 2005
- FDA, NCI united in pursuit of 2015 goal, Andrew von Eschenbach tells cancer center directors; says his appointment was necessary to “maintain the momentum of the FDA.”
- The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.
- NIH establishes new clinical science awards to eventually replace General Clinical Research Centers.
TCL
Vol.
31
No.
39
October 28, 2005
- Charles Balch resigns as ASCO executive vice president; Joseph Bailes named interim EVP.
- Also HHS Inspector General is reviewing Lester Crawford’s departure from FDA.
- Senate approves NIH funding bill. NCI awards $25 million to eight institutions for patient navigator programs; $35 million awarded for nanotechnology partnerships.
- NIH-funded HapMap consortium publishes first phase of catalog.
- NIH begins transition to electronic grant submissions; seeks comment on options for NRSA funding.
CCL
Vol.
28
No.
10
October 28, 2005
- Vaccine Prevented Cervical Pre-Cancers, Non-Invasive Cancers In Phase III Trial
- SWOG Seeks NSCLC Patients For Study Of Gender Differences In Lung Cancer
- NCI Begins Ovarian Cancer Trial To Build Blood Samples
- Aromasin Approved By FDA For ER+ Early Breast Cancer
- NSAIDs Cut Oral Cancer Risk But Raise Smokers’ Heart Risk
- HRT Doesn’t Raise Cancer Risk Following Oophorectomy
- Obesity, Faster Weight Gain, Linked To Poor Prognosis
- Study Finds Up To 12 Percent Of Specimens Misdiagnosed
- NCI Cooperative Group, Cancer Center Trials Listed